Abstract | OBJECTIVE: The optimal serum urate levels necessary for elimination of tissue deposits of monosodium urate in patients with chronic gout is controversial. This observational, prospective study evaluates the relationship between serum urate levels during therapy and the velocity of reduction of tophi in patients with chronic tophaceous gout. METHOD: Sixty-three patients with crystal-confirmed tophaceous gout were treated with allopurinol, benzbromarone, or combined therapy to achieve serum uric acid levels less than the threshold for saturation of urate in tissues. The tophi targeted for evaluation during followup were the largest in diameter found during physical examination. RESULTS: CONCLUSION:
|
Authors | Fernando Perez-Ruiz, Marcelo Calabozo, Jose I Pijoan, Ana M Herrero-Beites, Ana Ruibal |
Journal | Arthritis and rheumatism
(Arthritis Rheum)
Vol. 47
Issue 4
Pg. 356-60
(Aug 2002)
ISSN: 0004-3591 [Print] United States |
PMID | 12209479
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Gout Suppressants
- Uric Acid
- Benzbromarone
- Allopurinol
|
Topics |
- Adult
- Aged
- Allopurinol
(therapeutic use)
- Benzbromarone
(therapeutic use)
- Crystallization
- Drug Therapy, Combination
- Female
- Gout
(blood, complications, drug therapy)
- Gout Suppressants
(therapeutic use)
- Humans
- Male
- Middle Aged
- Prospective Studies
- Uric Acid
(blood)
|